Psychiatrist.comOral Glutamatergic Modulation with Dextromethorphan and Piracetam for Refractory Bipolar Disorder with Obsessive-Compulsive Disorder: Three Consecutive Cases From Routine Practice

Three consecutive patients with refractory bipolar disorder plus OCD achieved sustained remission using an oral NMDA-AMPA glutamatergic protocol after failing SSRIs, antipsychotics, and mood stabilizers. The regimen combined dextromethorphan, low-dose fluoxetine, and piracetam, producing PHQ-9 scores dropping from 14-27 to 6-9 and near-complete resolution of compulsive behaviors.

Clinical Considerations

• All three patients had failed high-dose SSRIs, atypical antipsychotics, and standard mood stabilizers before responding to glutamatergic modulation
• Piracetam’s AMPA potentiation was the critical second step: dextromethorphan alone produced only partial improvement across all cases
• Transient hypomanic activation was managed by reducing dextromethorphan while maintaining piracetam, suggesting differential dose titration is feasible
• Case series only; no controlled trial data exist yet for this protocol in bipolar-OCD comorbidity

Practice Applications

• Recognize bipolar-OCD comorbidity as a distinct phenotype requiring glutamatergic rather than serotonergic approaches
• Avoid high-dose SSRIs as primary OCD treatment in bipolar patients given substantial manic switch risk
• Document treatment-refractory cases thoroughly before considering off-label glutamatergic protocols
• Await controlled trial data before adopting this regimen outside of specialized or academic settings

More in Bipolar Disorder